Circassia announced that the U.S. Food and Drug Administration (FDA) has approved its duaklir for maintenance treatment of chronic obstructive pulmonary disease (COPD)

Yesterday was World Asthma Day, and today, the US Drug Administration passed the approval of AstraZeneca new drugs In the future, there will be more new drugs for COPD maintenance treatment, and how about the specific effect We hope to enter the Chinese market as soon as possible, waiting for market test Duaklir is a drug jointly launched by Circassia pharmaceutical and AstraZeneca to treat chronic obstructive pulmonary disease The drug is a fixed dose combination of long-acting muscarinic antagonist (Lama) propidium bromide (400mcg) and long-acting β - agonist (Laba) formoterol fumarate (12mcg) The drug is administered by breathing twice a day through the stimulator pressair Steve Harris, chief executive of circle Asia, said: "we are very pleased that the FDA has approved the launch of duaklir, believing that the drug will provide valuable treatment options for a large number of COPD patients in the United States." "Duaklir has further strengthened our R & D line of respiratory products, and we look forward to launching them in the US in the next few months." The approval is based on data from three phase III clinical studies (acliform, August and amplify) and phase IV ascent studies, which show that the treatment can effectively reduce the deterioration of COPD Disclaimer: This article is reprinted by yaozhi.com The copyright belongs to the original author The purpose of reprinting is to transmit more information and does not represent the view of this platform If the content, copyright and other issues of the work are involved, please contact the message on this website, and we will delete the content as soon as possible